Your session is about to expire
← Back to Search
ALK-001 oral capsule for Age-Related Macular Degeneration (SAGA Trial)
SAGA Trial Summary
This trial will last for approximately 3 years.
SAGA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSAGA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SAGA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have dry AMD causing vision loss in at least one eye.I have vision loss in at least one eye due to dry AMD.I do not have any health issues that would stop me from following the study's requirements.
- Group 1: ALK-001
- Group 2: Placebo
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any other similar medications to ALK-001 oral capsule?
"As of right now, there are a total of 9 ongoing clinical studies surrounding ALK-001 oral capsule. Out of those 9, 2 are currently in Phase 3. The oral capsule is being tested in 14 different locations, with the majority of those trials taking place in Somerville, Massachusetts."
ALK-001 oral capsule is typically used to treat what type of condition?
"ALK-001 oral capsules can be used to correct vitamin deficiencies that lead to health problems, such as vitamin d or A deficiency."
Are new patients being enrolled in this clinical trial currently?
"Presently, this clinical trial is not recruiting patients. However, it was first posted on May 7th, 2019 and was most recently updated on February 15th, 2022. There are a total of 331 clinical trials actively enrolling patients with geographic atrophy and 9 studies for ALK-001 oral capsule that are actively looking for patients."
How many people are being given the chance to participate in this experiment?
"This research is not looking for patients at the moment. The trial was first posted on 07/05/2019 and was last updated on 15/02/2022. If you are interested in other studies, there are currently 331 trials enrolling patients with geographic atrophy and 9 trials for ALK-001 oral capsule admitting patients."
Have there been other similar trials to this one in the past?
"Alkeus Pharmaceuticals, Inc. first conducted a clinical trial for ALK-001 oral capsule in 2015. Since then, 9 other trials have been completed in 11 cities across 2 countries. A total of 203 trials have been completed for this medication since 2015."
Has ALK-001 been cleared for public consumption by the FDA?
"ALK-001 oral capsule has received a score of 3 for safety. This is because it is a Phase 3 trial, meaning that there is both some efficacy data and multiple rounds of safety data."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger